Blockade of the malignant phenotype by <i>&#x03B2;</i>-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes - Université de Rennes Access content directly
Journal Articles Oncotarget Year : 2017

Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes

Abstract

A structure-based virtual screening of over 400,000 small molecules against the constitutive proteasome activity followed by in vitro assays led to the discovery of a family of proteasome inhibitors with a sulfonyl piperazine scaffold. Some members of this family of small non-peptidic inhibitors were found to act selectively on the β2 trypsin-like catalytic site with a preference for the immunoproteasome β2i over the constitutive proteasome β2c, while some act on the β5 site and post-acid site β1 of both, the immunoproteasome and the constitutive proteasome. Anti-proliferative and anti-invasive effects on tumor cells were investigated and observed for two compounds. We report novel chemical inhibitors able to interfere with the three types of active centers of both, the immuno- and constitutive proteasomes. Identifying and analyzing a novel scaffold with decorations able to shift the binders’ active site selectivity is essential to design a future generation of proteasome inhibitors able to distinguish the immunoproteasome from the constitutive proteasome.
Fichier principal
Vignette du fichier
14428-214561-3-PB.pdf (3.49 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

hal-01459714 , version 1 (24-03-2017)

Licence

Attribution

Identifiers

Cite

Bruno O. Villoutreix, Abdel-Majid Khatib, Yan Cheng, Maria A. Miteva, Xavier Maréchal, et al.. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes. Oncotarget, 2017, 8 (6), pp.10437-10449. ⟨10.18632/oncotarget.14428⟩. ⟨hal-01459714⟩
163 View
135 Download

Altmetric

Share

Gmail Facebook X LinkedIn More